Treatment for MS does well in phase 3 trials

(since this is one of the misdiagnoses of Lyme, maybe it will interest some)

Anti-CD20 antibody wows in multiple sclerosis

• Cormac Sheridan

Nature Biotechnology

33,

1215–1216

(2015)

doi:10.1038/nbt1215-1215

Published online

09 December 2015

Article tools

• Citation
• Reprints
• Rights & permissions
• Article metrics

Jessica Wilson / Science Source

MRI of normal brain (left) and one with multiple sclerosis (right).

Roche plans to seek approval early in the new year for its anti-CD20 antibody ocrelizumab as therapy in both forms of multiple sclerosis (MS)—primary progressive and relapsing remitting—following positive outcomes from recent phase 3 trials.

_______________________________________________